Literature DB >> 7840782

Reversal of methylmercaptopurine ribonucleoside cytotoxicity by purine ribonucleosides and adenine.

E H Stet1, R A De Abreu, J P Bökkerink, L H Lambooy, T M Vogels-Mentink, J J Keizer-Garritsen, F J Trijbels.   

Abstract

6-Methylmercaptopurine ribonucleoside-5'-phosphate (MeSPuRMP), the sole metabolite of 6-methylmercaptopurine ribonucleoside (MeSPuRib), is a strong inhibitor of purine de novo synthesis, inducing depletion of intracellular purine nucleotides and subsequent cell death in several tumor cell lines. In this study prevention of MeSPuRib cytotoxicity by compounds of the purine salvage pathway was studied in Molt F4 human malignant T-lymphoblasts. Adenosine, adenine and inosine were able to prevent depletion of the adenine nucleotide pool when used in combination with 0.5 microM MeSPuRib, but had virtually no effect on depletion of guanine nucleotides. Nevertheless, these three purine compounds were able to reduce the cytotoxic effects induced by MeSPuRib. Addition of guanosine to cells treated with 0.5 microM MeSPuRib normalized the guanine nucleotide pool, but adenine nucleotides remained depleted. Under these conditions, inhibition of cell growth was significantly decreased. With the combination of guanosine and 10 microM MeSPuRib, cytotoxicity was increased compared to 10 microM MeSPuRib alone, associated with a depletion of adenine nucleotides to 9% of untreated cells. Since cell growth and cell viability of Molt F4 cells are less inhibited by MeSPuRib under conditions where adenine nucleotide depletion is prevented by purine compounds (and where the other nucleotides are depleted) we conclude that depletion of adenine nucleotides is an important factor in MeSPuRib cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7840782     DOI: 10.1016/0006-2952(94)00387-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

Review 1.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

Review 2.  Acute lymphoblastic leukemia: optimizing treatment strategies in children.

Authors:  Ajay Vora
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.

Authors:  F Innocenti; R Danesi; A Di Paolo; B Loru; C Favre; M Nardi; G Bocci; D Nardini; P Macchia; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia.

Authors:  D-C Liang; C-P Yang; H-C Liu; T-H Jaing; S-H Chen; I-J Hung; T-C Yeh; T-H Lin; C-L Lai; C-Y Lai; L-Y Shih
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

5.  Enhancing the Antiviral Potency of Nucleobases for Potential Broad-Spectrum Antiviral Therapies.

Authors:  Ruben Soto-Acosta; Tiffany C Edwards; Christine D Dreis; Venkatramana D Krishna; Maxim C-J Cheeran; Li Qiu; Jiashu Xie; Laurent F Bonnac; Robert J Geraghty
Journal:  Viruses       Date:  2021-12-14       Impact factor: 5.048

6.  Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells.

Authors:  Mariia Yuneva; Nicola Zamboni; Peter Oefner; Ravi Sachidanandam; Yuri Lazebnik
Journal:  J Cell Biol       Date:  2007-07-02       Impact factor: 10.539

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.